authID to Report Second Quarter 2023 Financial Results on August 10, 2023

Conference call and webcast to follow at 5:30 p.m. EDT

DENVER, July 31, 2023 (GLOBE NEWSWIRE) —

authID
 [Nasdaq: AUID], a leading provider of secure identity verification and authentication solutions, today announced the Company will report financial results for the second quarter ended June 30, 2023 on Thursday, August 10 after market close. Following the earnings release, authID Chief Executive Officer Rhon Daguro and Chief Financial Officer Annie Pham will host a webcast and conference call at 5:30 p.m. EDT to discuss the financial results and provide a corporate update.

  Participants can pre-register in advance of the call to receive the dial in number and a PIN, which cannot be shared with others.

About authID® Inc.

At authID (Nasdaq: AUID), We Are Digital Identity®. authID provides secure identity verification and authentication through Verified™, an easy-to-integrate strong authentication platform. Verified combines document-based identity verification with strong FIDO2 passwordless device authentication and cloud biometrics to deliver identity-first cybersecurity for both workforce and consumer applications. Powered by sophisticated biometric and artificial intelligence technologies, authID establishes trusted digital identities, binds an identity to provisioned devices, and eliminates the risks of passwords to deliver the faster, frictionless, and accurate user identity solutions demanded by today’s digital ecosystem.

authID Media Contact

Graham N. Arad
General Counsel
[email protected]



Duos Technologies Group Sets Second Quarter 2023 Earnings Call for Monday, August 14, 2023 at 4:30 PM ET

JACKSONVILLE, Fla., July 31, 2023 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), through its operating subsidiary Duos Technologies, Inc., a provider of machine vision and artificial intelligence that analyzes fast moving vehicles, will hold a conference call on Monday, August 14, 2023 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2023. Financial results will be issued via press release prior to the call.

Duos management will host the conference call, followed by a question-and-answer period.

  Date: Monday, August 14, 2023
  Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
  U.S. dial-in: 877-407-3088
  International dial-in: 201-389-0927
  Confirmation: 13740403
     

Please call the conference telephone number 5-10 minutes prior to the start time of the conference call. An operator will register your name and organization.

If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at 949-574-3860.

The conference call will be broadcast live via telephone and available for online replay via the investor section of the Company’s website here.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., designs, develops, deploys and operates intelligent vision based technology solutions supporting rail, logistics, intermodal and government customers that streamline operations, improve safety and reduce costs. The Company provides cutting edge solutions that automate the mechanical and security inspection of fast-moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. For more information, visit www.duostech.com.


Forward- Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies, and prospects — both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. All forward-looking statements attributable to Duos Technologies Group, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b6c12547-4b21-4eba-8c3f-79cdb8d5e28b

 



Contacts

Corporate

Fei Kwong, Director, Corporate Communications

Duos Technologies Group, Inc. (Nasdaq: DUOT)
904-652-1625
[email protected]

Investor Relations

Matt Glover or Tom Colton

Gateway Investor Relations

949-574-3860

[email protected]

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region

DUBLIN, Ireland and BRIDGEWATER, N.J. and NANTOU, Taiwan, July 31, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) today announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® (icosapent ethyl) across 10 countries, including nine in Southeast Asia (the Association of Southeast Asian Nations – ASEAN) and South Korea.

VAZKEPA capsules have been approved and commercialized in a number of global markets, including the U.S. and European markets, as the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid (EPA).

“We are excited to announce this exclusive partnership with Lotus, a leading pharmaceutical commercialization partner in Asia,” said Patrick Holt, President & CEO, Amarin. “Lotus’ strong commercialization capabilities and footprint across ASEAN markets and South Korea make them the ideal partner to help us expand patient access to VAZKEPA — an innovative treatment option to reduce cardiovascular risk — across the region and fuel our international growth.”

Petar Vazharov, Chief Executive Officer of Lotus, commented, “We are thrilled to embark on this strategic partnership with Amarin. This agreement aligns seamlessly with Lotus’ strategic objective to bring novel and transformative treatments to patients and allows us the opportunity to further leverage our commercial infrastructure that we have built in key markets across Asia.”

The ASEAN region and South Korea includes a total of 14 million statin-treated patients representing a total hyperlipidemia market of approximately $2 billion.i The largest markets within the ASEAN region include Thailand, Malaysia and Philippines.i Cardiovascular disease (CVD) remains the leading cause of morbidity, mortality, and health care costs in South Korea.ii

Under the terms of the agreement, Lotus will have exclusive rights to distribution and commercial promotion for VAZKEPA in South Korea and nine countries in ASEAN: Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. As part of the agreement, Amarin will receive an upfront payment as well as pricing and reimbursement and sales milestone payments based on net sales of the product. Amarin will be responsible for supplying finished product to Lotus at a pre-defined supply price.

About Amarin
   

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.

About Lotus Pharmaceuticals

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safer and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. 

About VAZKEPA® (icosapent ethyl) Capsules 

VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid. Since launch, icosapent ethyl has been prescribed over 18 million times. In addition to the United States, icosapent ethyl is approved and sold in Canada, Lebanon, the United Arab Emirates under the brand name VASCEPA. In March 2021, marketing authorization was granted to icosapent ethyl in the European Union under the brand name VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease or diabetes and at least one other cardiovascular risk factor1. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Denmark, Finland, Austria and the UK.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s partnership in the ASEAN region and South Korea and the potential impact in those territories; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; and the overall potential and future success of VASCEPA/VAZKEPA generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information
   
Investor Inquiries:
Jordan Zwick
Amarin Corporation plc
[email protected]   
  
Media Inquiries:  
Mark Marmur 
Amarin Corporation plc   
[email protected]

1 Vazkepa® (icosapent ethyl): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf   [accessed Nov 2022]

i Source: IQVIA MAT 1Q 2022
ii Implementation of National Health Policy for the Prevention and Control of Cardiovascular Disease in South Korea: Regional-Local Cardio-Cerebrovascular Center and Nationwide Registry. Korean Circulation Journal 2021; 51(5): 383-398. Published online: 12 April 2021
DOI: https://doi.org/10.4070/kcj.2021.0001



Aemetis Biogas Closes $25 Million USDA-Guaranteed Financing to Fund Digesters for Eight Additional Dairies to Produce Renewable Natural Gas


AB-2 Phase Fully Funded with $34.4 million from 20-year $25 million USDA Loan and $9.4 million of Aemetis Funded Equity; Expands Aemetis Biogas from Seven Operating Dairies to 15 Dairies to Supply an Estimated 400,000 MMBtu per year of Carbon Negative RNG for Use as Transportation Fuel to Replace Diesel

CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWireAemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on negative carbon intensity products, announced today the closing of its second $25 million, 20-year term loan guaranteed by the U.S. Department of Agriculture (USDA) for a total of $50 million of Aemetis Biogas project financing arranged by Greater Commercial Lending (GCL) in the past nine months.

The Aemetis Biogas Central Dairy RNG Project is now fully funded to build biogas digesters and related assets for eight additional dairies using the $9.4 million of equity financing already provided by Aemetis and the $25 million of new debt financing guaranteed by the USDA. Magnolia Bank of Elizabethtown, Kentucky provided the primary funding for the $25 million loan to Aemetis Biogas 2, LLC (AB-2), a wholly-owned subsidiary of Aemetis, Inc.

“The USDA Renewable Energy for America Program (REAP) provides long term, 20-year financing that enables the construction of projects that improve air quality and reduce carbon pollution such as the Aemetis Biogas Central Dairy Digester Project,” stated Eric McAfee, Chairman and CEO of Aemetis. “We appreciate the good working relationship that has been developed with the team at Greater Commercial Lending and we are pleased to have Magnolia Bank as the new primary lender for the AB-2 phase of the project.”

Aemetis Biogas has built and is fully operating dairy biogas digesters for seven dairies, a 40-mile biogas pipeline, the central biogas-to-RNG production facility and the PG&E gas utility interconnection unit. When completed, the biogas digesters for the combined 15 dairies are designed to produce more than 400,000 MMBtus per year of carbon negative renewable natural gas.

The long-term, 20-year project financing was guaranteed by the USDA through the Rural Energy for America Program (REAP) and carries approximately an 8.75% fixed interest rate for the first five years. With two REAP loans closed and three more REAP loans in process, Aemetis Biogas is currently arranging $125 million of 20-year debt funding for the development, construction and operation of the Aemetis Central Dairy Digester project which has already signed 37 dairies and plans to build digesters for 65 dairies within the next 60 months.

Aemetis Biogas is building passive solar anaerobic digesters at dairies to capture biomethane from animal waste. After removal of key contaminants and gas pressurization at the dairy, a biogas pipeline connects the dairies to a central facility located at the Keyes ethanol plant where the biogas is converted into below zero carbon intensity RNG. The RNG is tested and odorized in an interconnection unit, then injected into the Pacific Gas and Electric (PG&E) gas pipeline for delivery to transportation fuel customers throughout California. In addition to delivery of RNG through third parties, Aemetis is building an onsite RNG fueling station to fuel local trucks.

About 25% of the methane emissions in California are emitted from dairy waste lagoons. When fully built, the Aemetis biogas project plans to connect dairy digesters spanning more than 65 dairy farms, producing more than 1,650,000 MMBtu of renewable natural gas from captured dairy methane each year. The project is designed to reduce greenhouse gas emissions equivalent to an estimated 6.8 million metric tonnes of carbon dioxide over ten years, equal to removing the emissions from approximately 150,000 cars per year.

About Aemetis

Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis has completed Phase 1 and is expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis also owns and operates a 50 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing the Carbon Zero sustainable aviation fuel (SAF) and renewable diesel fuel biorefineries in California to utilize distillers corn oil and other renewable oils to produce low carbon intensity renewable jet and diesel fuel using cellulosic hydrogen from waste orchard and forest wood, while pre-extracting cellulosic sugars from the waste wood to be processed into high value cellulosic ethanol at the Keyes plant. Aemetis holds a portfolio of patents and exclusive technology licenses to produce renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

About Greater Commercial Lending


Greater Commercial Lending
(GCL) is a credit organization that brings together banks, credit unions and other lenders to provide U.S. government-guaranteed loans to businesses and initiatives in rural and under-served markets throughout the U.S. and its territories. It helps finance key infrastructure services, like power, renewable energy, transportation and fiber optics, as well as schools, hospitals, restaurants, agriculture, hotels and manufacturers. GCL partners with the U.S. Small Business Administration (SBA) and the U.S. Department of Agriculture (USDA), which guarantee loans, to arrange credit at favorable terms. GCL’s network of lenders includes nearly 200 banks, credit unions and other financial institutions.

About Magnolia Bank

Founded in 1919 in Magnolia, Kentucky, Magnolia Bank has grown to become a top-producing originator with offices located throughout the U.S. through an active commercial lending, leasing, and mortgage business. Jerry Spruill serves as the Senior Vice President of Magnolia Guaranteed Lending, a division of Magnolia Bank, which focuses on the origination and development of USDA guaranteed loans. Magnolia Guaranteed Lending seeks to provide USDA guaranteed loans throughout the U.S. and its territories.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the development and construction of the Aemetis Biogas RNG project, expected greenhouse gas emission reductions from the completed Aemetis Biogas RNG project, the development of biogas upgrading facilities at the Keyes plant and our ability to promote, develop and deploy technologies to produce renewable fuels and biochemicals.  Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties.  Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations

Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected]

Company Investor Relations/

Media Contact:

Todd Waltz
(408) 213-0940
[email protected]



Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:

  • Nadim Ahmed, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023 on Monday, August 7, 2023 at 10:30 a.m. EDT
  • Cullinan’s management team will be hosting 1-on-1 meetings at the 2023 Wedbush PacGrow Healthcare Conference in New York, NY on Tuesday, August 8, 2023

BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About Cullinan Oncology

Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.

Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.

Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
[email protected]

Media
Rose Weldon
+1 215.801.7644
[email protected]



Wearable Devices to Host Spatial Input Interactions Webinar on August 2, 2023

– The Webinar will Address the Various Aspects of Designing a Neural Input Wristband for Creating Intuitive User Experiences for Spatial Interactions –

YOKNEAM ILLIT, ISRAEL, July 31, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in AI-powered touchless sensing wearables, will host a webinar to discuss the Company’s recently published white paper, “Designing a Neural Input Wristband for Extended Reality Experiences” on Wednesday, August 2 at 11 am ET.

During the webinar, Barry Kaplan, Executive Vice President of United States Operations, will address the various aspects of designing a neural input wristband for spatial computing and extended reality experiences. Mr. Kaplan will discuss the design considerations and requirements for a wearable, touchless, and hands-free neural input interface that utilizes familiar gestures in relaxed and comfortable spatial body postures, resulting in the development and production of an intuitive and fashionable neural input platform for the consumer market.

Interested parties that would like to learn more can register for this webinar via the link below.

Who should attend: engineers, product managers and executives across all industries who are seeking to better facilitate the broad deployment of a wearable, touchless and hands-free input across their products and solutions.

Webinar/Registration Link:
https://events.zoom.us/ev/AoaO-skKNV3_kl6S9PL4rIf30dkau3B4ctlH-PH2HX9ukG8wnstD~AggLXsr32QYFjq8BlYLZ5I06Dg

About Wearable Devices Ltd.

 Wearable Devices Ltd. is a growth company developing AI-based neural input interface technology for the B2C and B2B markets. The Company’s flagship product, the Mudra Band for Apple Watch, integrates innovative AI-based technology and algorithms into a functional, stylish wristband that utilizes proprietary sensors to identify subtle finger and wrist movements allowing the user to “touchlessly” interact with connected devices. The Company also markets a B2B product, the Mudra Inspire, which utilizes the same technology and functions as the Mudra Band and is available to businesses on a licensing basis. Wearable Devices Is committed to creating disruptive, industry leading technology that leverages AI and proprietary algorithms, software, and hardware to set the input standard for the Extended Reality, one of the most rapidly expanding landscapes in the tech industry. The Company’s common stock trades on the Nasdaq market under the symbol “WLDS”.

Investor Relations Contact

Walter Frank
IMS Investor Relations
203.972.9200
[email protected]



INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

Management to host conference call and webcast at 4:30 pm ET on that day

Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Monday, August 7, 2023 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023 and to provide a corporate update.


Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.

Date: August 7, 2023
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-877-407-0784
Participant Dial-in (international): 1-201-689-8560
Conference ID: 13739436

A live audio webcast of the call can be accessed clicking here or using this link:
https://callme.viavid.com/viavid/?callme=true&passcode=13739436&h=true&info=company&r=true&B=6

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 14 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13739436.

About INmune Bio, Inc.


INmune
 
Bio
 
Inc
.
 is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:

David Moss, CFO
(858) 964-3720
[email protected]

Investor Contact:



Jason Nelson
Core IR
(516) 842-9614 Ext: 823



Alignment Healthcare Spotlights Improved Senior Health Outcomes, Greater Access to Care in 2nd Annual ESG Report

Latest data details how Medicare Advantage company drove greater reduction in members’ blood sugar levels and diabetes-related deaths, provided more rides to care and healthy meals in 2022 compared to 2021

ORANGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today released its second annual environmental, social and governance (ESG) report.

From double-digit percentage reductions in hospitalizations to a 1.5-point average reduction in blood sugar levels, the report highlights how Alignment continues to deliver better care at lower costs across key metrics in 2022 when compared to traditional Medicare fee-for-service (FFS). The company also helped reduce carbon dioxide emissions associated with clinical visits by 600 metric tons (or 1.5 million miles driven by an average gasoline-powered vehicle) by conducting over 120,000 telehealth visits. This is equivalent to removing 134 gasoline-powered vehicles from the road for one year, according to the Environmental Protection Agency.

“Our commitment to doing well by doing good is foundational to who we are and what we do, and this is reflected in our 2022 ESG report metrics and accomplishments,” said John Kao, Alignment Healthcare founder and CEO. “We improved health outcomes for our seniors. We also introduced new products that address social determinants of health, expanded our mental health and psychiatric services and established an ESG steering committee to help elevate our sustainability efforts.”

In 2022, Alignment continued to transform health care for its members by:

  • Driving better, more positive health outcomes: Alignment’s focus on high-quality, low-cost care resulted in a 48% reduction in 2022 emergency room (ER) visits among Alignment members compared to 2019 Medicare FFS ER visits; 37% reduction in hospital admissions among Alignment members compared to 2019 Medicare FFS admissions; and a 26% reduction in Alignment member 30-day readmission rates compared to 2019 Medicare FFS readmission rates.
  • Addressing unique health needs with coordinated care: Proactive diabetes care through Alignment’s Care Anywhere program drove a 1.5-point average reduction in members’ average blood sugar levels (HbA1c) after 12 months of enrollment – up from the 1.2-point average reduction reported in Alignment’s 2021 ESG report. This is estimated to drive a greater than 21% reduction in diabetes-related deaths – up from the 20% reported in Alignment’s 2021 ESG report.
  • Increasing services that address social determinants of health (SDoH): Alignment provided more than 147,600 rides (inclusive of wheelchair assistance) – an increase of 62% from the 91,000 rides Alignment provided in 2021 – reducing transportation barriers so members can get to the care they need. The company also delivered more than 23,600 meals to members to address food insecurity, up 42% from the 16,600 meals noted in Alignment’s 2021 ESG report.
  • Improving health care access and quality: According to Alignment’s inaugural Social Threats to Aging Well in America survey released in 2022, an estimated 14% of seniors cite the lack of responsive care from medical providers as one of the obstacles to health care. Alignment alleviates health care access and quality problems by considering a member’s full health care journey. In 2022, there were 196,000 health care interactions and member touchpoints, 25,500 “just checking-in” calls and 12,000 new member welcome calls.
  • Providing proactive support to boost medication adherence and health screenings: Continuous monitoring of members’ health profiles and timely alerts are integral to Alignment’s holistic approach to health care. In 2022, Alignment members had a 92% medication adherence for diabetes (4.89% higher than the average for Medicare Advantage Prescription Drug [MAPD] contracts), 92% medication adherence for hypertension (3.26% higher than the average for MAPD contracts) and 90% medication adherence for cholesterol (2.86% higher than the average for MAPD contracts). Additionally, among our California HMO contracts, 80% of Chronic Condition Special Needs Plan (C-SNP) and Dual-Eligible Special Needs Plan (D-SNP) enrollees completed a health risk assessment, 81% of female members completed breast cancer screenings, 72% of female members completed body/bone density scans and 80% of members completed colorectal screening.
  • Expanding mental health and psychiatric services: Alignment offers a range of personalized therapy programs, including individual counseling and group therapy, to support a member’s health journey.

Additionally in 2022, Alignment continued to operate responsibly and sustainably while promoting a diverse, inclusive culture by:

  • Increasing sustainability in its operations: By engaging with eco-conscious partners and measuring company actions, Alignment generated 92% energy savings from the transition to cloud-based data platform computing resources and 79% energy savings from the transition to cloud-based data platform storage resources. Additionally, 100% of sales agent vehicles were hybrid in 2022.
  • Enhancing its commitment to ESG: In the past year, Alignment hired a senior manager to oversee ESG efforts, established six major ESG goals the company will work toward through 2025 and created an ESG Steering Committee to regularly meet and track progress of the goals.
  • Serving through diversity of representation: Sixty-six percent of Alignment employees, 50% of its executive team and 43% of its members are African American, Asian, Hispanic/Latino, Indigenous or of other non-white background, while 71% of its employees and 55% of its members are women.

“Since our inaugural ESG report, we have made great strides as an organization, but we will continue to aim higher and strive to do better by our environment and our members. We look forward to providing updates on our progress and innovation as we build a sustainable future,” Kao added.

To learn more about Alignment’s impact and its ongoing ESG work, visit www.alignmenthealthcare.com/esg.

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor; changes in laws and regulations applicable to our business model; risks related to our indebtedness, including the potential for rising interest rates; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; the impact of shortages of qualified personnel and related increases in our labor costs; and the impact of COVID-19 on our business and results of operation. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2022, and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Investor Contact

Harrison Zhuo
[email protected]

Media Contact

Priya Shah
mPR, Inc. for Alignment Health
[email protected]

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Alignment Healthcare Publishes 2nd Annual ESG Report: Medicare Advantage company’s environmental, social and governance efforts in 2022 show positive impact on health care outcomes.



RYVYL to Announce Second Quarter 2023 Financial Results on Monday, August 14, 2023

SAN DIEGO, CA, July 31, 2023 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions, will report financial results for the second quarter on Monday, August 14, 2023.

RYVYL management will host a conference at 4:30 p.m. Eastern Time on Monday, August 14, 2023 to discuss second quarter 2023 financial results, provide a corporate update and end with a question and answer session. To participate, please use the following information and submit your questions in writing prior to the call at [email protected].

Q
2
202
3
Conference Call and Webcast

Date: August 14, 2023
Time: 4:30 p.m. Eastern Time
US Dial In: 1-844-826-3035
International Dial In: 1-412-317-5195
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1626960&tp_key=56d4b5f445
Call me: Link

Please dial in at least 10 minutes before the start of the call to ensure timely participation. Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me link for instant telephone access to the event and enter pass code 4459816. The Call me link will be made active 15 minutes prior to scheduled start time.

To listen to a recording of the call available through October 14, 2023, dial 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter access ID 10181432. A webcast will also be available for 90 days on the IR section of the RYVYL website or by clicking the webcast link above.

About RYVYL

RYVYL Inc. (NASDAQ:RVYL) was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation capabilities, RYVYL is reinventing the future of financial transactions using its coyni® stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017 in San Diego, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity theft protection and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. www.ryvyl.com.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.

Investor Relations Contact

Mark Schwalenberg
MZ Group – MZ North America
312-261-6430
[email protected]
www.mzgroup.us



Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Initial data expected in first half of 2024

NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3 Cyprus2+ study following completion of dosing and safety review in the first cohort. The company’s investigational AAV9 gene therapy is designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion, with the goal of normalizing copper metabolism in patients with Wilson disease.

In the first dose cohort, UX701 has been well tolerated with no unexpected related treatment emergent adverse events observed as of July 11, 2023. The Data Safety Monitoring Board recommended that the company proceed with dosing patients at the higher dose of 1.0 x 10^13 GC/kg. Investigators have dosed the first patient and have identified and screened the remaining four patients for dosing in Cohort 2. The company is on track to complete enrollment in Stage 1 of the Phase 1/2/3 trial this year and expects to share initial data in the first half of 2024.

“We are encouraged by the safety data and early signals of the establishment of normal trafficking of copper observed in Cohort 1 and with acceleration of enrollment following improvements in study design and entry criteria,” said Eric Crombez, M.D., chief medical officer at Ultragenyx. “The shift to open label design and broadening of inclusion criteria allows us to enroll subjects who may not be well managed on current standard of care with chelators and/or zinc.”

U.S. residents can learn more by visiting ultraclinicaltrials.com.


Cyprus



2+


Phase 1/2/3 study design

This study evaluating UX701 for the potential treatment of Wilson disease is designed with three stages. During the first stage, the safety and efficacy of up to three dose levels of UX701 will be evaluated over the course of 52 weeks and a dose will be selected for further evaluation in Stage 2. In this first stage, 15 patients will be enrolled into three sequential dosing cohorts to evaluate doses of 5.0 x 10^12 GC/kg, 1.0 x 10^13 GC/kg, and 2.0 x 10^13 GC/kg.

In Stage 2, a new cohort of patients will be randomized 2:1 to receive the selected dose of UX701 or placebo. The primary safety and efficacy analyses will be conducted at Week 52 of Stage 2. The primary efficacy endpoints are change in 24-hour urinary copper concentration and percent reduction in standard of care (SOC) medication by Week 52. After the initial 52-week study period, all patients will have long term follow up in stage 3.

About Wilson Disease

Wilson disease is a rare inherited disorder caused by mutations in the ATP7B gene, which results in deficient production of ATP7B, a protein that transports copper. Loss of function of this copper-binding protein results in the accumulation of copper in the liver and other tissues, most notably the central nervous system, and also the failure to properly distribute copper by ceruloplasmin. Patients with Wilson disease experience hepatic, neurologic and/or psychiatric problems. Those with liver disease can experience such symptoms as fatigue, lack of appetite, abdominal pain and jaundice, and can progress to fibrosis, cirrhosis, life-threatening liver failure and death. Wilson disease can be treated by reducing copper absorption or removing excess copper from the body using life-long chelation therapy, but unmet needs exist because some treated patients experience clinical deterioration and severe side effects. Wilson disease affects more than 50,000 individuals in the developed world.

About UX701

UX701 is an investigational AAV9 gene therapy designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion. It has been shown in preclinical studies to normalize copper trafficking and excretion from the body. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to UX701.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit ultragenyx.com.

Ultragenyx Forward-Looking Statements and Use of Digital Media

Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx’s expectations and projections regarding its future operating results and financial performance, business plans and objectives for UX701, expectations regarding the tolerability and safety of UX701, and future clinical and regulatory developments for UX701 are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals, the ability of the company to successfully develop UX701, the company’s ability to achieve its projected development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain activities on the company’s behalf , smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2023, and its subsequent periodic reports filed with the SEC.

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (

https://ir.ultragenyx.com/

) and LinkedIn website (

https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/

).

Contacts

Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-475-6370
[email protected]

Media
Jeff Blake
415-612-7784
[email protected]